Abstracts tagged "SLE"

Abstract Number: 658 • 2019 ACR/ARP Annual Meeting
Disentangling Connective Tissue Diseases: Overlaps and Disparities in Clinical Diagnosis, Classification Criteria and Autoantibodies – Results from the Lupus Extended Autoimmune Phenotype Study
Sarah Dyball¹, John Reynolds ², Hector Chinoy ², Tracy Briggs ², Sahena Haque ³, Eoghan McCarthy ⁴, Ellen Bruce ⁵, Ariane Herrick ⁶, Ian Bruce ⁷ and Ben Parker ⁸, ¹University of Manchester, Manchestser, United Kingdom, ²University of Manchester, Manchester, United Kingdom, ³University Hospital South Manchester, Manchester, United Kingdom, ⁴Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, England, United Kingdom, ⁵Central Manchester University Hospitals, Manchester, United Kingdom, ⁶Salford Royal Foundation Trust, Manchester, United Kingdom, ⁷University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ⁸University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom; Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, United Kingdom
Background/Purpose: Connective tissue diseases (CTDs) are a heterogeneous group of diseases with overlapping clinical features and shared immunopathology. In routine practice, a clinician diagnosis is…
Abstract Number: 897 • 2019 ACR/ARP Annual Meeting
Mortality Rates After Coronary Revascularization Procedures Among Systemic Lupus Erythematosus Compared to Diabetes Mellitus and General Population Medicaid Patients
Medha Barbhaiya¹, Sarah Chen ², Candace Feldman ³, Hongshu Guan ³, Brendan Everett ⁴ and Karen Costenbader ⁴, ¹Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Brigham and Women's Hospital and Harvard Medical School, Boston, ³Brigham and Women's Hospital, Boston, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Despite similar myocardial infarction risks in SLE and diabetes mellitus (DM) patients, individuals with SLE enrolled in Medicaid had substantially higher rates of coronary…
Abstract Number: 1571 • 2019 ACR/ARP Annual Meeting
Validity Evidence Supports the Use of Automated Neuropsychological Assessment Metrics (ANAM) as a Screening Tool for Cognitive Impairment in Patients with Systemic Lupus Erythematosus
Oshrat Tayer-Shifman¹, Robin Green ², Dorcas Beaton ³, Lesley Ruttan ², Joan Wither ⁴, Maria Tartaglia ⁵, Mahta Kakvan ¹, Sabrina Lombardi ², Nicole Anderson ¹, Jiandong Su ¹, Dennisse Bonilla ¹, Moe Zandy ¹, May Choi ⁶, Marvin Fritzler ⁶ and Zahi Touma ⁷, ¹University Health Network, University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³St. Michael's Hospital, Toronto, ON, Canada, ⁴University Health Network, Krembil Research Institute, Toronto, ON, Canada, ⁵University Health Network, University of Toronto, Toronto, ON, Canada, ⁶Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁷University Health Network, University of Toronto, Toronto, Canada
Background/Purpose: Cognitive impairment (CI) is highly prevalent in Systemic Lupus Erythematosus (SLE). Screening for CI in SLE may be delayed, if relying on the American…
Abstract Number: 1844 • 2019 ACR/ARP Annual Meeting
The Contribution of Disease Activity, Depression, and Anxiety to Health-Related and Non-Health-Related Quality of Life in US and Filipino Patients with SLE
Alexandra Watts¹, Desiree Azizoddin ², Shadi Gholizadeh ³, Sarah Mills ⁴, Geraldine Zamora ⁵, Daniel Wallace ⁶, Meenakshi Jolly ⁷, Michael Weisman ⁸ and Perry Nicassio ⁹, ¹University of California, Los Angeles, Los Angeles, CA, ²Dana-Farber Cancer Institute, Boston, MA, ³McGill University, Montreal, Canada, ⁴Lineberger Comprehensive Cancer Center, Chapel Hill, NC, ⁵Manila Doctors Hospital, Manila, Philippines, ⁶Cedars-Sinai Medical Center/University California at Los Angeles, Los Angeles, CA, ⁷Rush University Medical Center, Chicago, IL, ⁸David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁹David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: It is well known that patients with SLE are often afflicted with deficits in quality of life and problems with physical impairment and psychosocial…
Abstract Number: 2549 • 2019 ACR/ARP Annual Meeting
Population Pharmacokinetics of Atacicept in Systemic Lupus Erythematosus (SLE) – an Analysis of Three Clinical Trials
Maria Pitsui ¹, Orestis Papasouliotis², Colm Farrell ¹, Pascal Girard ², Oezkan Yalkinoglu ³ and Cristina Vazquez-Mateo ⁴, ¹ICON Plc, Dublin, Ireland, ²Merck Institute for Pharmacometrics, Lausanne, Switzerland, ³Merck KGaA, Darmstadt, Germany, ⁴EMD Serono Research and Development Institute, Inc., Billerica, MA
Background/Purpose: Atacicept targets the B-cell stimulating factors BLyS and APRIL and has been shown to reduce SLE disease activity. The aim of the analysis was…
Abstract Number: 662 • 2019 ACR/ARP Annual Meeting
Utility of a Mobile Phone Based Application to Collect Patient-Reported Outcome Information from People Living with Systemic Lupus Erythematosus
Brooke Williams¹, Bridget Muckian ¹, Claire Dykas ², Christine Peschken ³, Richard Furie ⁴, Elena Massarotti ⁵, Vanja sikirica ⁶, Steven Gilbert ⁷, Martin Hodge ⁷ and Peter Lipsky ⁸, ¹AMPEL BioSolutions, Charlottesville, VA, ²AmpelBioSolutions, Charlottesville, VA, ³University of Manitoba, Winnepeg, Canada, ⁴Northwell Health, Great Neck, NY, ⁵Brigham and Women's Hospital/Harvard Medical School, Boston, MA, ⁶Pfizer, Boston, MA, ⁷Pfizer, Boston, ⁸AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: Patient Reported Outcomes (PROs) can provide important data about the impact of a disease on an individual and/or the quality of the response to…
Abstract Number: 942 • 2019 ACR/ARP Annual Meeting
A Randomized Prospective Trial to Assess the Clinical Utility of Multianalyte Assay with Complement Activation Products in Diagnosing Systemic Lupus Erythematosus
Daniel Wallace¹, Roberta Alexander ², Tyler O'Malley ³, Arezou Khosroshahi ⁴, Mehrnaz Hojjati ⁵, Konstantinos Loupasakis ⁶, Jeffrey Alper ⁷, Yvonne Sherrer ⁷, Maria Fondal ⁷, Rajesh Kataria ⁸, Tami Powell ², Claudia Ibarra ², Sonali Narain ⁹, Elena Massarotti ¹⁰, Arthur Weinstein ² and Thierry Dervieux ², ¹Cedars Sinai Medical Center/UCLA, Los Angeles, CA, ²Exagen, Vista, CA, ³Exagen, Oceanside, CA, ⁴Emory University, Atlanta, GA, ⁵Department of Rheumatology, Loma Linda University, Loma Linda, CA, ⁶MedStar Washington Hospital Center, Department of Rheumatology, Washington, DC, ⁷BendCare Rheumatology, Naples, FL, ⁸Southern Ohio Rheumatology, Wheelersburg, OH, ⁹Northwell Health, Great Neck, Long Island, NY, ¹⁰Brigham and Women's Hospital/Harvard Medical School, Boston, MA
Background/Purpose: Cell-Bound Complement Activation Products (CB-CAPs) in multianalyte assay panel (MAP) is a diagnostic immunology laboratory test with established clinical validity in distinguishing systemic lupus…
Abstract Number: 1574 • 2019 ACR/ARP Annual Meeting
Causes of Death in SLE: Analysis of Inpatient Death from 2000-2018 in a Tertiary Care Hospital in India
Sarit Sekhar Pattanaik¹, Hafis Muhammed ², Amita Aggarwal ³, Able Lawrence ⁴, Vikas Agarwal ², Durga P Misra ², Latika Gupta ⁴ and Ramnath Misra ⁴, ¹Sanjay Gandhi post graduate institute of medical sciences, Lucknow, Uttar Pradesh, India, ²SGPGI, Lucknow, Uttar Pradesh, India, ³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, Uttar Pradesh, India
Background/Purpose: Mortality in Systemic lupus erythematosus (SLE) has reduced over the years but it is still two to three folds as compared to general population.…
Abstract Number: 1864 • 2019 ACR/ARP Annual Meeting
Gaps in Care for Patients with SLE: Data from the ACR’s RISE Registry
Gabriela Schmajuk¹, Zara Izadi ², Michael Evans ³ and Jinoos Yazdany ⁴, ¹UCSF, SFVAMC Division of Rheumatology, San Francisco, CA, ²UCSF Division of Rheumatology, San Francisco, ³University of California San Francisco, San Francisco, ⁴UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: Although multiple national quality measures focus on the management and safety of rheumatoid arthritis, few measures address the care of patients with SLE. We…
Abstract Number: 2555 • 2019 ACR/ARP Annual Meeting
Antimalarial-Induced Cardiomyopathy: Outcome in 10 Patients
Konstantinos Tselios¹, Dafna Gladman ², Shadi Akhtari ³, Paula Harvey ³, Kate Hanneman ⁴ and Murray Urowitz ⁵, ¹University Health Network, University of Toronto, Toronto, Canada, ²Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ³Women's College Hospital, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Antimalarial-induced cardiomyopathy (AMIC) is a hypertrophic cardiomyopathy with conduction system disorders, cardiac biomarker abnormalities and a short-term mortality of 45%. Data on the reversibility…
Abstract Number: 667 • 2019 ACR/ARP Annual Meeting
The PROMIS-29 as a Measure of Type 1 and 2 SLE Activity
Nathaniel Harris¹, Amanda Eudy ², Megan Clowse ², Lisa Criscione-Schreiber ², Jayanth Doss ², Rebecca Sadun ², Jennifer Rogers ² and Kai Sun ², ¹Duke University Medical Center, Durham, NC, ²Duke University, Durham
Background/Purpose: We have developed a new conceptual model that characterizes lupus into subtypes based on physician- and patient-reported measures: Type 1 is assessed by the…
Abstract Number: 975 • 2019 ACR/ARP Annual Meeting
Functional Impairment of Mitf and the MiT Transcription Factor Family Dysregulates B Cell Activation and Function
Abhimanyu Amarnani¹, Ramile Dilshat ², Nikita Malakhov ³, Brian Ghezelaiagh ⁴, Chongmin Huan ¹, Erna Magnusdottir ², Eirikur Steingrimsson ² and Christopher Roman ¹, ¹SUNY Downstate Medical Center, Brooklyn, ²University of Iceland Biomedical Center, Reykjavik, Iceland, ³SUNY Downstate Medical Center, New York Presbyterian-Weill Cornell Medical Center, Brooklyn, ⁴SUNY Downstate Medical Center, Stony Brook University, Brooklyn
Background/Purpose: Autoreactive B cells are central in the development of many autoimmune diseases, such as systemic lupus erythematosus (SLE), and are normally eliminated or inactivated…
Abstract Number: 1575 • 2019 ACR/ARP Annual Meeting
Lymphocyturia Is a Good and Cheap Biomarker for Active Lupus Nephritis and Is Sensitive to Change
Sarit Sekhar Pattanaik¹, Ankita Singh ², Shilpa Venkataraman ³, Ramnath Misra ⁴, Vinita Agrawal ² and Amita Aggarwal ⁵, ¹Sanjay Gandhi post graduate institute of medical sciences, Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Post Graduate institute of medical science, Lucknow, India, Lucknow, Uttar Pradesh, India, ³Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, Uttar Pradesh, India, ⁵Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Multiple urinary biomarkers have been described for lupus nephritis, however none has reached the clinic due to either complex methodology or low discriminatory power.…
Abstract Number: 1941 • 2019 ACR/ARP Annual Meeting
Interactions Between Genome-Wide Genetic Factors and Current Smoking in Determining SLE Risk
Jing Cui¹, Soumya Raychaudhuri ², Cameron Speyer ², Susan Malspeis ², Hongshu Guan ³, Xinyi Liu ², Jessica Williams ², Emma Davenport ⁴, Rachel Knevel ⁵, Elizabeth Karlson ² and Karen Costenbader ², ¹Brigham Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, ⁴Sanger Institute, Cambridge, United Kingdom, ⁵Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: We have previously reported that current smoking (or having recently quit within 4 years) was associated with elevated risk of SLE, in particular anti-dsDNA+…
Abstract Number: 2577 • 2019 ACR/ARP Annual Meeting
SLE Disease Activity May Be Associated with Choroidal Thickness
Iris Lee¹, Brigid Marshall ¹, Prabha Ranganathan ², Seth Eisen ³, Rithwick Rajagopal ¹, Alfred Kim ³ and Tingting Li ¹, ¹Washington University in St Louis, St Louis, ²Washington University in St Louis, St Louis, MO, ³Washington University School of Medicine, Saint Louis, MO
Background/Purpose: SLE is an autoimmune disease with widespread organ involvement. High disease activity has previously been associated with higher risk of organ damage and mortality.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].